SCHEMBL1648097

SCHEMBL1648097

COC(=O)c1c(CS(=O)(=O)c2ccccc2)ccc(-c2cocn2)c1OC

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.36
IMPDH2 P12268 4/20 0.36
IMPDH1 P20839 1/20 0.36
ALDH1A1 P00352 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
LTB4R Q15722 1/20 0.35
LTB4R2 Q9NPC1 1/20 0.35
ALOX5AP P20292 1/20 0.35
POLB P06746 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KEAP1 Q14145 5/20 0.34
NFE2L2 Q16236 2/20 0.34
PTGDR Q13258 1/20 0.34
TP53 P04637 1/20 0.33
GLA P06280 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1649941 0.92 LTB4R (0.36) KMT2AIMPDH2IMPDH1ALDH1A1L3MBTL1
SCHEMBL18801448 0.81 L3MBTL1 (0.39) KMT2AIMPDH2IMPDH1ALDH1A1L3MBTL1
SCHEMBL1648347 0.78 METAP2 (0.46) KMT2AALDH1A1L3MBTL1POLBKEAP1
SCHEMBL1648251 0.78 ALDH1A1 (0.40) KMT2AALDH1A1L3MBTL1POLBSMN1; SMN2
SCHEMBL1648416 0.78 KDM4E (0.40) KMT2AALDH1A1L3MBTL1POLBKEAP1
SCHEMBL1648525 0.77 MAPT (0.44) KMT2AALDH1A1L3MBTL1POLBSMN1; SMN2
SCHEMBL435766 0.76 ALDH1A1 (0.44) KMT2AALDH1A1L3MBTL1POLBNPC1
SCHEMBL1648095 0.76 KEAP1 (0.37) KMT2AALDH1A1L3MBTL1ALOX5APPOLB
SCHEMBL1648306 0.75 KMT2A (0.42) KMT2AALDH1A1L3MBTL1POLBKEAP1
SCHEMBL1648261 0.74 ALDH1A1 (0.40) KMT2AALDH1A1POLBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC (US) 2016-02-25 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
EP-2486004-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME Zafgen Corporation (US) 2012-08-15 EP disclosed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME METAP2, DNPEP, STS KMT2A 666/4885IMPDH2 451/4885IMPDH1 800/4885
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same METAP2, DNPEP, STS KMT2A 666/4885IMPDH2 451/4885IMPDH1 800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.